Breakthrough Tracker record

A Streptomyces megacluster encodes a naturally coordinated multi-drug antibiotic system

A conserved Streptomyces biosynthetic megacluster was shown to produce four natural-product families plus streptavidin that converge on bacterial biotin metabolism through complementary mechanisms. Stravidin S2 and alpha-Me-KAPA acted synergistically and improved efficacy in a mouse model of multidrug-resistant E. coli infection.

← Back to the filtered Breakthrough Tracker

Stable ID
science-2026-streptomyces-antibiotic-megacluster
Revision
science-2026-streptomyces-antibiotic-megacluster.v1
Field
Biology · Microbiology and antibiotic discovery
Evidence
Tier 2 · Peer reviewed: Yes
Record state
Current · Peer-reviewed preclinical result
Last checked

AI role

No substantive AI role was reported.

Record details

Problem or result
Conventional antibiotic discovery often isolates one molecule at a time and may miss naturally co-evolved combinations that attack a pathway at several points.
Authors
R. Gordzevich, M. Xu, W. Wang et al.
Institutions
McMaster University Institute of Infectious Disease Research; Biochemistry and Biomedical Sciences; David Braley Centre for Antibiotic Discovery
Result date
June 24, 2026

Why it matters

The work reveals naturally encoded combination therapy as an underexplored antibiotic-discovery strategy.

Limits

The efficacy evidence is preclinical; pharmacokinetics, toxicity, dosing, manufacturing and resistance evolution in humans are unknown. These compounds are not an approved treatment.

Sources

  1. Primary: Nature primary paper
  2. Primary: Code archive
  3. Independent: Nature editorial reporting

Correction and revision history

  1. 2026-06-24 — Mechanistic and mouse-efficacy study published in Nature.

Machine-readable: JSON v1 · CSV v1 · Schema v1

This individual record remains noindex until a story-specific featured image passes Kingy’s rendered-pixel visual review. The source-linked tracker hub remains the public index.